Breckenridge Pharmaceutical announced the U.S. Food and Drug Administration (FDA) has granted final approval for its Abbreviated New Drug Application for Rivastigmine Transdermal System in 4.6mg/24 hours, 9.5mg/24 hours and 13.3mg/24 hours strengths (generic for Exelon® Patch by Novartis). Breckenridge's Rivastigmine Transdermal System was developed in collaboration with Welding GMBH & Co. KG and SK Chemicals Co. Exelon® Patch and its therapeutic equivalents generated annual sales of $161 million during the twelve months ending September 30, 2019, according to industry sales data. Breckenridge plans to launch the product immediately.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!